Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including ABVD, BEACOPP, and stem-cell transplantation. Brentuximab vedotin has shown significant clinical activity, with a manageable safety profile, in patients with...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 14; no. 13; pp. 1348 - 1356
Main Authors:	Younes, Anas, Connors, Joseph M, Park, Steven I, Fanale, Michelle, O'Meara, Megan M, Hunder, Naomi N, Huebner, Dirk, Ansell, Stephen M
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.12.2013 Elsevier Limited
Subjects:	Adult Aged Anemia - chemically induced Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - administration & dosage Bleomycin - adverse effects Brentuximab Vedotin Chemotherapy Dacarbazine - administration & dosage Dacarbazine - adverse effects Disease prevention Dose-Response Relationship, Drug Doxorubicin - administration & dosage Doxorubicin - adverse effects Drug Administration Schedule Drug dosages Female Hematology Hematology, Oncology and Palliative Medicine Hodgkin Disease - diagnosis Hodgkin Disease - drug therapy Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Infusions, Intravenous Kaplan-Meier Estimate Lymphoma Male Middle Aged Neutropenia Neutropenia - chemically induced Peripheral neuropathy Radiation therapy Toxicity Treatment Outcome Vinblastine - administration & dosage Vinblastine - adverse effects United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!